Results of a randomized, double-blind study of romiplostim versus placebo in patients with low/intermediate-1-risk myelodysplastic syndrome and thrombocytopenia. (2014)

First Author: Giagounidis A
Attributed to:  MRC Centre for Transplantation funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1002/cncr.28663

PubMed Identifier: 24706489

Publication URI: http://europepmc.org/abstract/MED/24706489

Type: Journal Article/Review

Volume: 120

Parent Publication: Cancer

Issue: 12

ISSN: 0008-543X